Literature DB >> 17651940

Cellular signaling in normal and cancerous stem cells.

Edgar Grinstein1, Peter Wernet.   

Abstract

Self-renewing divisions of normal and cancerous stem cells are responsible for the initiation and maintenance of normal and certain cancerous tissues, respectively. Recent findings suggest that tumor surveillance mechanisms can reduce regenerative capacity and frequency of normal stem cells, thereby contributing to tissue aging. Signaling pathways promoting self-renewal of stem cells can also drive proliferation in cancer. The BMI-1 proto-oncogene is required for the maintenance of tissue-specific stem cells and is involved in carcinogenesis within the same tissues. BMI-1 promotes self-renewal of stem cells largely by interfering with two central cellular tumor suppressor pathways, p16(Ink4a)/retinoblastoma protein (Rb) and ARF/p53, whose disruption is a hallmark of cancer. Nucleolin, an Rb-associated protein, is abundant in proliferating cancerous cells and likely contributes to the maintenance of human CD34-positive stem/progenitor cells of hematopoiesis. Elucidation of the involvement of proto-oncogenes and tumor suppressors in the maintenance of stem cells might have therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17651940     DOI: 10.1016/j.cellsig.2007.06.021

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  22 in total

1.  Control of AC133/CD133 and impact on human hematopoietic progenitor cells through nucleolin.

Authors:  S Bhatia; S Reister; C Mahotka; R Meisel; A Borkhardt; E Grinstein
Journal:  Leukemia       Date:  2015-06-19       Impact factor: 11.528

Review 2.  Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer.

Authors:  Junan Li; Ming Jye Poi; Ming-Daw Tsai
Journal:  Biochemistry       Date:  2011-06-06       Impact factor: 3.162

Review 3.  Cancer stem cells: potential target for bioactive food components.

Authors:  Young S Kim; William Farrar; Nancy H Colburn; John A Milner
Journal:  J Nutr Biochem       Date:  2012-07       Impact factor: 6.048

Review 4.  Targeting the perpetrator: breast cancer stem cell therapeutics.

Authors:  Arindam Pal; Kelli E Valdez; Martha Z Carletti; Fariba Behbod
Journal:  Curr Drug Targets       Date:  2010-09       Impact factor: 3.465

5.  Bmi1 is required for tumorigenesis in a mouse model of intestinal cancer.

Authors:  M A Maynard; R Ferretti; K I Hilgendorf; C Perret; P Whyte; J A Lees
Journal:  Oncogene       Date:  2013-08-19       Impact factor: 9.867

6.  BMI-1, a promising therapeutic target for human cancer.

Authors:  Min-Cong Wang; Chun-Li Li; Jie Cui; Min Jiao; Tao Wu; L I Jing; Ke-Jun Nan
Journal:  Oncol Lett       Date:  2015-06-11       Impact factor: 2.967

Review 7.  Therapeutic targeting of the p53 pathway in cancer stem cells.

Authors:  Varun V Prabhu; Joshua E Allen; Bo Hong; Shengliang Zhang; Hairong Cheng; Wafik S El-Deiry
Journal:  Expert Opin Ther Targets       Date:  2012-09-24       Impact factor: 6.902

Review 8.  Targeting stem cells-clinical implications for cancer therapy.

Authors:  Lan Chun Tu; Greg Foltz; Edward Lin; Leroy Hood; Qiang Tian
Journal:  Curr Stem Cell Res Ther       Date:  2009-05       Impact factor: 3.828

9.  Interleukins, laminin and Epstein - Barr virus latent membrane protein 1 (EBV LMP1) promote metastatic phenotype in nasopharyngeal carcinoma.

Authors:  Michelle M S Chew; Sook-Yee Gan; Alan S B Khoo; Eng-Lai Tan
Journal:  BMC Cancer       Date:  2010-10-22       Impact factor: 4.430

10.  Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma.

Authors:  Lee Ridley; Ruman Rahman; Marie-Anne Brundler; David Ellison; James Lowe; Keith Robson; Emma Prebble; Inga Luckett; Richard J Gilbertson; Sheila Parkes; Vikki Rand; Beth Coyle; Richard G Grundy
Journal:  Neuro Oncol       Date:  2008-08-13       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.